OBJECTIVES:: To present demographics and characteristics of Latin American psoriasis patients. METHODS:: Data was obtained from the Adelphi Psoriasis Latin America Disease Specific Programme. Dermatologists completed patient record forms related to treatment practice, demographics and clinical characteristics for patients >18 years old diagnosed with moderate-severe psoriasis for over 1 year who had received at least one systemic treatment. Patients provided consent prior to completing forms related to their symptoms. RESULTS:: Dermatologists (n=144) from Brazil (n=40), Colombia (n=30), Argentina (n=35) and Mexico (n=39) had a mean (SD) of 17.6 (9.6) practice years and on average saw 118.5 patients/5-day week. The analysis included 941 patients from Brazil (n=320), Colombia (n=179), Argentina (n=209) and Mexico (n=233); 56.4% were male, with mean (SD) age 49.5 (13.8) years, mean (SD) BMI 27.4 (4.9), and mean (SD) disease duration 12.2 (10.8) years. At the time of survey 44.1% of patients were classified as moderate-severe, 63.4% had PGA score 2-5, 31.9% had BSA >10% and 31% were experiencing flare. Patients diagnosed as moderate-severe were undergoing treatment with biologic (32.7%), conventional systemic (53.4%) and combination therapy (12.6%); 48% moderate-severe patients were receiving a steroid and 13% phototherapy. Difficult to treat areas included scalp (40.0%), groin/genitals (11.5%) and palmar-plantar areas (20.8%). Most bothersome areas were scalp (29.2%), groin/genitals (9.9%), toes (8.1%) and soles of the feet (7.7%). Most common symptoms in patients regardless of severity were scaling (72.2%), inflamed skin (52.5%) and itching (44.5%). Comorbidities included hypertension (33.2%), hyperlipidemia (23.9%), anxiety (23.7%), depression (14.0%) and diabetes (18.1%). Approximately 60% were currently employed; of those unemployed or retired, 9% were unable to work due to psoriasis. CONCLUSIONS:: Psoriasis is a burdensome disease in Latin American patients due to its symptoms, impact on appearance, high incidence of comorbidities and presence of lesions in difficult to treat areas of the skin.